CIK 0000921299
- Non-accelerated filer
- Smaller reporting company
KYNTRA BIO, INC.
Sign in to watch- Ticker
- KYNB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770357827
- Phone
- +1 415-978-1200
- Business address
- 350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
- Former names
- FIBROGEN INC
- 4 Open-market sale Director sold 18,000 shares at $35.02 ($630,360)
- 4 Shares withheld for taxes SVP, Clinical Dev, Drug Safety gave up 5,221 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, Finance and CFO gave up 5,657 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, China Operations gave up 5,679 shares (to pay taxes)
- 4 Grant or award Chief Commercial Officer acquired 16,500 shares (grant or award)
- 4 Grant or award SVP, Clinical Dev, Drug Safety acquired 20,800 shares (grant or award)
- 4 Grant or award SVP, Finance and CFO acquired 21,700 shares (grant or award)
- 4 Grant or award SVP, China Operations acquired 21,700 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 82,000 shares (grant or award)
- 3/A Insider 3/A
- 4 Open-market sale Director sold 6,000 shares at an average $52.40 ($314,383)
- 4 Open-market sale Director sold 6,000 shares at $43.38 ($260,280)
- 4 Open-market sale Director sold 5,999 shares at $40.04 ($240,200)
- 4 Shares withheld for taxes Chief Executive Officer gave up 5,411 shares (to pay taxes)
- 4 Exercise or conversion Director acquired 6,000 shares (option exercise)
- 4 Open-market sale Director sold 6,001 shares at an average $40.40 ($242,455)
- 4 Open-market sale Chief Medical Officer sold 3,350 shares at $41.61 ($139,394)
- 4 Open-market sale SVP, Finance and CFO sold 3,068 shares at $43.60 ($133,765)
- 4 Shares withheld for taxes Chief Medical Officer gave up 3,292 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, Clinical Dev, Drug Safety gave up 2,728 shares (to pay taxes)
Page 11 of 38 · 760 filings